Insider Buying: Inovio Pharmaceuticals Director Purchases 40,600 Shares of Stock (INO)
Inovio Pharmaceuticals (NYSE:INO) Director Morton Collins acquired 40,600 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were purchased at an average price of $9.74 per share, with a total value of $395,444.00. Following the completion of the purchase, the director now directly owns 173,066 shares of the company’s stock, valued at approximately $1,685,663. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Inovio Pharmaceuticals (NYSE:INO) traded up 3.42% during mid-day trading on Thursday, hitting $10.27. 879,874 shares of the company’s stock traded hands. Inovio Pharmaceuticals has a one year low of $6.04 and a one year high of $15.80. The stock’s 50-day moving average is $10.33 and its 200-day moving average is $10.8. The company’s market cap is $620.3 million.
Inovio Pharmaceuticals (NYSE:INO) last released its earnings data on Monday, August 11th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.19) by $0.01. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $1.80 million. Analysts expect that Inovio Pharmaceuticals will post $-0.63 EPS for the current fiscal year.
INO has been the subject of a number of recent research reports. Analysts at Aegis upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 24th. They now have a $19.00 price target on the stock, up previously from $10.00. Four equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $20.20.
Inovio Pharmaceuticals, Inc is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.